Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout


  1. Sharma A, Kondo M, Iwahashi C, Parachuri N, Kumar N, Bandello F, et al. Approved biosimilar ranibizumab-a global update. Eye. 2023;37:200–2.

    Article  PubMed  Google Scholar 

  2. Sharma A, Parachuri N, Kumar N, Bandello B, Kuppermann BD. Emerging biosimilars for retinal diseases. Expert Rev Ophthalmol. 2022;17:383–6.

    Article  CAS  Google Scholar 

  3. Accessed June 2023

  4.,myopic%20choroidal%20neovascularization%20(mCNV). Accessed June 2023

  5. Accessed June 2023

  6. Accessed June 2023

  7. Accessed June 2023

  8.,fewer%20steps%20than%20the%20vial. Accessed June 2023

  9. Accessed June 2023

  10. Accessed June 2023

  11. Dingerkus VLS, Somfai GM, Kinzl S, Orgül SI, Becker MD, Heussen FM. Incidence of severe rise in intraocular pressure after intravitreous injection of aflibercept with prefilled syringes. Sci Rep. 2022;12:18136.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references



BDK acknowledges an unrestricted grant to the Gavin Herbert Eye Institute from Research to Prevent Blindness.

Author information

Authors and Affiliations



AS: conception, analysis, drafting, integrity check, final approval. AL, NP, NK, AR, BDK; drafting, revision, analysis, integrity check.

Corresponding author

Correspondence to Ashish Sharma.

Ethics declarations

Competing interests

AS: CONSULTANT: for Novartis, Allergan, Bayer, Lupin and Intas, Speaker fee Biogen. AL: CONSULTANT: Allergan, Novartis, Roche, Notal Vision, Fiorsightslabs, Beyeonics, Bayer Health Care. AR: Employee Intas Pharmaceuticals Ltd. FB: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. BDK: CLINICAL RESEARCH:, Alimera, Allegro, Allergan, Apellis, Boehringer Ingelheim, Clearside, Genentech, GSK, Ionis, jCyte, Novartis, Regeneron; CONSULTANT: Alimera, Allegro, Allergan/AbbVie, Boehringer Ingelheim, Clearside, Coherus, EyeBio, Eyedaptic, Galimedix, Genentech, Glaukos, IvericBio, jCyte, Novartis, Ocular Therapeutix, Regeneron, Revana, Theravance Biopharma. The other authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sharma, A., Loewenstein, A., Parachuri, N. et al. Biosimilar anti-VEGF- is prefilled syringe (PFS) a challenge?. Eye (2023).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI:

This article is cited by


Quick links